Sponsored Content by LabmanReviewed by Maria OsipovaOct 30 2025
In January 2025, Labman announced its largest project to date: the design, construction, and support of an innovative drug discovery platform for a leading global pharmaceutical company.
This cutting-edge facility is engineered to use artificial intelligence (AI) to dramatically shorten the time required for drug discovery cycles, accelerating the development of life-changing therapeutics.
The platform, supported by mobile robots, consisted of highly integrated modules and was developed over a two-year period beginning in January 2025. By automating and optimizing every phase of the DMTA cycle, the system aimed to speed up the identification and development of therapies for a wide range of diseases.
Image Credit: Labman
Working alongside the incredible team over the past four months has been a journey of innovation and collaboration, culminating in securing Labman's largest-ever deal, a milestone we’re all proud to celebrate. This achievement is a testament to what can be accomplished when dedication meets shared vision.
Matthew Smith, Global Business Development, Labman
In partnership with industry leaders, the synthesis platform was designed and constructed at Labman’s headquarters in North Yorkshire, incorporating sophisticated technologies to carry out each stage of the DMTA process.
Design – AI-driven algorithms are employed to analyze data and design new drug molecules.
Make – Researchers synthesize, purify, and analyze both individual compounds and larger compound sets with exceptional precision.
Test – Required assays are reformatted and selected, generating assay-ready plate generation, testing compound potency, and efficacy in cell-free and cell-based biological assays.
Analyze – Detailed compound profiling analyzes the results, providing insights that directly integrate results back into the design process, triggering iterative cycles.
Image Credit: Labman
This ambitious project highlights Labman’s leadership in providing cutting-edge automation solutions. The DMTA platform aimed to improve the efficiency of drug discovery and demonstrate the revolutionary potential of AI and automation in medical research.
Ian Riley, Managing Director at Labman, expressed his enthusiasm for the project:
This is an exciting time for Labman and a testament to the ingenuity and hard work of our team. This order demonstrates the trust our clients place in us to deliver groundbreaking solutions. We are thrilled to collaborate with industry leaders to revolutionise the drug discovery process and contribute to the development of life- changing medicines.
Ian Riley, Managing Director, Labman
Image Credit: Labman
Acknowledgements
Produced from materials originally authored by Katie Simpson, Content Lead at Labman.
About Labman
Labman is a global leader in creating custom automated laboratory technologies, products, and software that empower and advance scientific discovery. We collaborate across diverse industries, including medical, pharmaceutical, agritech, paints and coatings, and FMCG, to deliver innovative solutions. From our state-of-the-art manufacturing facilities, Labman’s multi-disciplinary teams design, build, and support systems used worldwide, enabling groundbreaking science in leading laboratories every day.
Labman in 2025
Video Credit: Labman
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.